PUBLISHER: The Business Research Company | PRODUCT CODE: 2127638
PUBLISHER: The Business Research Company | PRODUCT CODE: 2127638
Shotgun metagenomics clinical reporting refers to a diagnostic methodology that utilizes next-generation sequencing to examine all genetic material contained within a clinical sample. It enables comprehensive and unbiased identification of bacteria, viruses, fungi, and parasites without requiring targeted detection of specific organisms. The sequencing results are analyzed through bioinformatics tools to identify pathogens and antimicrobial resistance markers.
The primary product types of shotgun metagenomics clinical reporting include software and services. Software refers to digital platforms developed to analyze complex metagenomic sequencing data and generate clinical reports for diagnostic and research applications. These solutions analyze sample types including blood samples, stool samples, respiratory samples, cerebrospinal fluid samples, tissue biopsy samples, urine samples, and other body fluid samples and utilize sequencing technologies such as short read sequencing, long read sequencing, and hybrid sequencing. The key applications include infectious disease diagnostics, oncology, microbiome analysis, antimicrobial resistance, and others, while the end users include hospitals and clinics, diagnostic laboratories, research institutes, and others.
Tariffs are influencing the shotgun metagenomics clinical reporting market by increasing the cost of imported sequencing instruments, reagents, and high-performance computing infrastructure required for genomic analysis. This is reducing the affordability and scalability of clinical metagenomics testing, particularly in regions dependent on global supply chains such as Asia-Pacific and Latin America. Segments including sequencing technology platforms and bioinformatics software services are the most affected due to their reliance on cross-border hardware and cloud infrastructure ecosystems. However, tariffs are also encouraging the localization of sequencing workflows, regional manufacturing of consumables, and investment in domestic genomic diagnostic capabilities, which may strengthen long-term healthcare resilience and reduce dependence on imported technologies.
The shotgun metagenomics clinical reporting market research report is one of a series of new reports from The Business Research Company that provides shotgun metagenomics clinical reporting market statistics, including shotgun metagenomics clinical reporting industry global market size, regional shares, competitors with a shotgun metagenomics clinical reporting market share, detailed shotgun metagenomics clinical reporting market segments, market trends and opportunities, and any further data you may need to thrive in the shotgun metagenomics clinical reporting industry. This shotgun metagenomics clinical reporting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The shotgun metagenomics clinical reporting market size has grown rapidly in recent years. It will grow from $1.58 billion in 2025 to $1.83 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advancement of next-generation sequencing technologies enabling clinical adoption, increasing prevalence of infectious disease outbreaks driving diagnostic demand, growth in microbiology and clinical genomics research funding, expansion of hospital laboratory molecular testing infrastructure, rising awareness of antimicrobial resistance monitoring needs.
The shotgun metagenomics clinical reporting market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to expansion of precision medicine and personalized diagnostics adoption, increasing integration of AI in genomic data interpretation, growth in decentralized and point-of-care sequencing systems, rising demand for rapid pathogen detection in critical care settings, expansion of cloud-based bioinformatics platforms for clinical workflows. Major trends in the forecast period include ai-driven pathogen detection and automated clinical interpretation systems, cloud-based genomic data sharing platforms for real-time diagnostics, ultra-rapid sequencing workflows for point-of-care infectious disease detection, integrated antimicrobial resistance prediction using genomic analytics, decentralized sequencing systems for hospital-based rapid metagenomic testing.
The increasing prevalence of infectious diseases is expected to drive the growth of the shotgun metagenomics clinical reporting market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can spread among individuals, animals, or through environmental sources. The prevalence of infectious diseases is rising due to the increasing occurrence of disease outbreaks linked to greater global connectivity and population movement. Shotgun metagenomics clinical reporting supports infectious disease management by enabling rapid and comprehensive detection of pathogens, antimicrobial resistance markers, and co-infections from clinical samples, helping healthcare providers achieve accurate diagnosis and targeted treatment. For instance, in October 2024, according to the World Health Organization, a Switzerland-based public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, compared to 7.5 million people in 2022, reflecting an increase of around 9.3%. Therefore, the increasing prevalence of infectious diseases is driving the growth of the shotgun metagenomics clinical reporting market.
Major companies operating in the shotgun metagenomics clinical reporting market are focusing on the development of advanced solutions, such as respiratory-focused genomic panels, to analyze microbial cell-free DNA from targeted clinical fluids and enhance diagnostic standards for vulnerable patient populations. Respiratory-focused genomic panels are specialized applications of metagenomic sequencing designed to identify and sequence fragmented pathogen DNA directly from complex, matrix-specific biological fluids, such as lung wash samples, enabling rapid, culture-independent diagnosis of complex respiratory tract infections. For instance, in April 2025, Karius Inc. launched Karius Focus BAL, a comprehensive metagenomic sequencing test that uses bronchoalveolar lavage fluid to analyze microbial cell-free DNA. The diagnostic solution evaluates fluid samples directly to identify more than 500 pathogens, provides processed diagnostic results within one calendar day of receiving samples, and detects 50% more causes of infectious pneumonia compared to conventional testing approaches.
In April 2026, Karius Inc., a US-based infectious disease diagnostics company, partnered with Mayo Clinic Laboratories to broaden access to advanced metagenomic infectious disease testing. Through this partnership, Karius aimed to make its Karius Spectrum and Karius Focus | BAL tests available for ordering through Mayo Clinic Laboratories, enabling improved access to comprehensive pathogen detection and clinical diagnostic reporting. Mayo Clinic Laboratories is a US-based clinical laboratory services provider specializing in advanced diagnostic testing and laboratory medicine.
Major companies operating in the shotgun metagenomics clinical reporting market report are BaseClear B.V., BGI Genomics Co. Ltd., BugSeq Bioinformatics Inc., CD Genomics Inc., Cmbio, Eurofins Scientific, Genome Detective, Illumina Inc., Karius Inc., Macrogen Inc., Microba Life Sciences Limited, Novogene Co. Ltd., Nucleome Informatics Private Limited, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Psomagen Inc., QIAGEN N.V., Revvity Inc., Strand Life Sciences Private Limited, Synnovis Group LLP, Takara Bio Inc., Thermo Fisher Scientific Inc., Yaazh Xenomics Private Limited, Zymo Research Corporation
North America was the dominating region in the shotgun metagenomics clinical reporting market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the shotgun metagenomics clinical reporting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the shotgun metagenomics clinical reporting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The shotgun metagenomics clinical reporting market consists of revenues earned by entities by providing services such as end-to-end genomic diagnostic services, sample processing, next-generation sequencing, bioinformatics analysis, pathogen identification, antimicrobial resistance profiling, and clinical interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The shotgun metagenomics clinical reporting market also includes sales of benchtop dna sequencers, high-throughput sequencing systems, automated nucleic acid extraction systems, sample preparation workstations, and library preparation instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Shotgun Metagenomics Clinical Reporting Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses shotgun metagenomics clinical reporting market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for shotgun metagenomics clinical reporting ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The shotgun metagenomics clinical reporting market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.